We deliver process-embedded, GMP-compliant engineering solutions purpose-built for scalable monoclonal antibody (mAb) manufacturing, supporting clinical pilot lines and large-scale commercial production facilities. Our integrated service covers master process zoning, upstream cell culture suite design, downstream purification layout optimization, sterile formulation and fill-finish engineering, as well as full utility system integration and validation delivery. Centered on mAb-specific production characteristics including high-cell-density fermentation, multi-step chromatographic purification, strict host cell protein and DNA impurity control, and consistent product quality attributes, our process-driven design eliminates facility-process mismatches, stabilizes batch reproducibility and builds fully inspection-ready manufacturing infrastructure for global BLA submission and commercial supply.
Our mAb plant engineering follows the core principle of process reproducibility-oriented layout, risk-based contamination control, low-deviation scale-up architecture, and multi-product operational flexibility. We optimize unidirectional personnel and material flow, independent classified zoning and hierarchical pressure cascades to segregate upstream cultivation, downstream purification and sterile finishing areas. Fully standardized sanitary piping, zero-dead-volume fluid paths and validated CIP/SIP structures ensure stable impurity removal and consistent process performance across batch runs. Modular skid-compatible layout reserves flexible expansion interfaces to support titer improvement, capacity scaling and new antibody pipeline integration without major facility reconstruction.
All engineering specifications and process design logic fully align with FDA, EMA, ICH Q8/Q9/Q10 and ISPE biomanufacturing standards for monoclonal antibody therapeutics. We embed full lifecycle data integrity architecture compliant with 21 CFR Part 11, enabling complete traceability of critical process parameters, environmental conditions and batch production records. Strict cleanroom classification, bioburden control, cross-contamination mitigation and viral safety design meet global mAb batch consistency and comparability requirements, ensuring continuous audit readiness for international regulatory inspections and cross-border market authorization.
We provide end-to-end process-driven engineering services covering project feasibility evaluation, process sizing and scale-up verification, conceptual and detailed facility design, construction supervision, equipment skid integration, commissioning and full qualification dossier delivery. By tightly coupling facility architecture with mAb upstream and downstream process logic, we minimize process deviation, reduce operational failure risks and improve overall production yield. Clients obtain highly stable, reproducible and regulation-friendly mAb manufacturing environments to accelerate clinical progression, lower operational costs and strengthen long-term market competitiveness.
